期刊
LEUKEMIA & LYMPHOMA
卷 50, 期 6, 页码 944-951出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428190902926973
关键词
Chronic myeloid leukemia; intermittent imatinib therapy; complete cytogenetic response; complete molecular response
资金
- Ministry of Science and Technology [R21-2007000-10041-0]
- Korea Health 21 RD Project [01-PJ10-PG6-01GN16-0005]
- Ministry of Health and Welfare, Republic of Korea
Although imatinib is considered as a front line therapy in patients with chronic myeloid leukemia (CML), it is still unclear whether transient imatinib discontinuation may adversely affect the outcome. This study was conducted to investigate long-term outcome after discontinuation and resumption of imatinib, and to determine whether intermittent imatinib therapy can be employed in patients with CML. Twenty six Philadelphia chromosome positive (Ph+) patients with CML discontinued imatinib when they achieved complete cytogenetic response (CCyR) or complete molecular response (CMR), and they were retreated with imatinib in case of hematologic, cytogenetic or molecular relapse. Except one patient who progressed and two patients who are in persistent molecular remission without imatinib resumption, all of 23 patients are maintaining the best response achieved after imatinib resumption with a median follow-up of 44 months. This study shows that although imatinib cannot be discontinued completely, intermittent therapy can be considered for the treatment of patients with CML in particular situations.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据